Zydus Cadila bags final approval for Bumetanide Tablets from USFDA

Pharma major Zydus Cadila received final approval for Bumetanide Tablets USP from the US Food and Drug Administration (USFDA) on Wednesday, post market hours. The tablet used to treat edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome.   

Recently, the company had also bagged the final approval from the USFDA for marketing Methylprednisolone Cinacalcet Hydrochloride tablets. The Cadila group now has 185 approvals after this approval from USFDA.

The company had posted nearly 198.73 per cent decline in its net profit at Rs 661.90 crore in the third quarter of the fiscal year 2018 on a year on year basis.  

The stock touched an intraday high of Rs. 416.50 per share and an intraday low of Rs. 404.25 per share on Wednesday on BSE. The stock had touched its 52-week high of Rs. 558 per share on June 12, 2017 and its 52-week low of Rs. 361.45 per share on March 23, 2018 on BSE, respectively. 

On Wednesday, Cadila Healthcare closed at Rs 406.20, down by 1.44 per cent, while, S&P BSE Sensex ended at 35,176.42 level, up by 0.05 per cent.